Products /
Primary Antibodies /
ATIC (F6Z3O) Rabbit Monoclonal Antibody

ATIC (F6Z3O) Rabbit Monoclonal Antibody #66095

Filter:

Product Specifications

REACTIVITY	H M R
SENSITIVITY	Endogenous
MW (kDa)	65
Source/Isotype	Rabbit IgG

Application Key:

WB-Western Blotting
IP-Immunoprecipitation

Species Cross-Reactivity Key:

H-Human
M-Mouse
R-Rat

Product Information

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Protocol

Specificity / Sensitivity

ATIC (F6Z3O) Rabbit Monoclonal Antibody recognizes endogenous levels of total ATIC protein.

Species Reactivity:

Human, Mouse, Rat

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro212 of human ATIC protein.

Background

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase (ATIC) is a bifunctional enzyme, catalyzing the last two steps of de novo purine synthesis (DNPS), converting 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) to inosine monophosphate (IMP). Proliferating cells require enhanced nucleotide synthesis, leading to upregulation of genes associated with DNPS and purine salvage pathways. Altered purine metabolism is linked to increased cell proliferation and cancer development and progression. Enhanced ATIC expression is observed in a variety of cancers and is associated with poor prognosis, promoting cell growth, migration, and resistance to some therapeutic interventions (1-4). Altered purine metabolism also correlates with the progression of Parkinson’s disease (PD). LRRK2 mutations are the most common genetic cause of PD. Research suggests that ATIC and its substrate AICAR may regulate LRRK2 expression levels and toxicity (5). The LRRK2 G2019S mutation, which increases kinase activity, is the most prevalent mutation among those with LRRK2-associated PD. Notably, ATIC was observed to be the most downregulated protein in a cohort of LRRK2 G2019S carriers. These findings suggest that ATIC may be a viable target for therapeutic intervention in PD (6).

Alternate Names

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase; 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase; 5-aminoimidazole-4-carboxamide-1-beta-D-ribonucleotide transformylase/inosinicase; AICAR; AICAR formyltransferase; AICAR formyltransferase/IMP cyclohydrolase bifunctional enzyme; AICAR transformylase; AICAR transformylase/inosine monophosphate cyclohydrolase; AICARFT; AICARFT/IMPCHASE; ATIC; Bifunctional purine biosynthesis protein ATIC; Bifunctional purine biosynthesis protein ATIC, N-terminally processed; Bifunctional purine biosynthesis protein PURH; epididymis secretory sperm binding protein Li 70p; FLJ93545; HEL-S-70p; IMP cyclohydrolase; IMP synthase; IMPCHASE; Inosine 5'-monophosphate cyclohydrolase; Inosinicase; Phosphoribosylaminoimidazolecarboxamide formyltransferase; phosphoribosylaminoimidazolecarboxamide formyltransferase/IMP cyclohydrolase; PUR9; PURH

Database Links

UniProt ID: P31939

Entrez-Gene Id: 471

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

For Research Use Only. Not for Use in Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit our Trademark Information page.